Quest Diagnostics Incorporated (DGX) : Traders are bullish on Quest Diagnostics Incorporated (DGX) as it has outperformed the S&P 500 by a wide margin of 1.94% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.07%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.13% in the last 1 week, and is up 2.99% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 1.05% and the 50-Day Moving Average is 5.36%. Quest Diagnostics Incorporated (NYSE:DGX): On Fridays trading session , Opening price of the stock was $85.82 with an intraday high of $86.04. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $85.51. However, the stock managed to close at $85.79, a loss of 0.31% for the day. On the previous day, the stock had closed at $86.06. The total traded volume of the day was 657,854 shares.
The company Insiders own 1.5% of Quest Diagnostics Incorporated shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -5.11% . Institutional Investors own 97.33% of Quest Diagnostics Incorporated shares. During last six month period, the net percent change held by insiders has seen a change of -6.99%. Also, Equity Analysts at the Jyske Bank downgrades the rating on Quest Diagnostics Incorporated (NYSE:DGX). The brokerage firm has issued a Sell rating on the shares. The rating by the firm was issued on June 24, 2016.
Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business, consists of two parts, develops and delivers diagnostic testing, information and services to patients, physicians, health plans, hospitals, accountable care organizations (ACOs), integrated delivery networks (IDNs), other commercial laboratories, patients and other customers. Diagnostics Information Services business also provides diagnostic information services, which includes providing clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Companys other businesses, including central laboratory testing for pharmaceutical and medical device clinical trials, risk assessment services, diagnostic products and healthcare information technology.